We have observed
6 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after September 17, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
NOVEL USES OF RECOMBINANT CLOSTRIDIAL NEUROTOXINS WITH DECREASED DURATION OF EFFECT
USE OF RECOMBINANT CLOSTRIDIAL NEUROTOXINS FOR THE TREATMENT OF PATIENTS HAVING CERTAIN MUSCLE-RELATED DISORDERS
NOVEL RECOMBINANT BOTULINUM TOXIN WITH ACCELARATED ONSET OF EFFECT
NOVEL RECOMBINANT BOTULINUM NEUROTOXINS WITH A STABILIZED LIGHT CHAIN